{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 1944251, "items": [{"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T06:15:13Z", "timestamp": 1575180913832}, "reference-count": 32, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "9", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2013, 3, 20]]}, "abstract": "<jats:sec><jats:title>Purpose</jats:title><jats:p> Elesclomol, an investigational first-in-class compound, induces oxidative stress, triggers mitochondrial-induced apoptosis in cancer cells, and shows synergy with taxanes in tumor models. Following completion of a phase II trial of elesclomol in combination with paclitaxel that met its primary end point of progression-free survival (PFS), this randomized, double-blind, controlled phase III study was conducted to confirm the efficacy and tolerability of elesclomol in combination with paclitaxel versus paclitaxel alone in patients with advanced melanoma. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Patients with stage IV chemotherapy-naive melanoma (n = 651) were randomly assigned 1:1 to paclitaxel 80 mg/m<jats:sup>2</jats:sup> either alone or in combination with elesclomol 213 mg/m<jats:sup>2</jats:sup> administered weekly for 3 weeks of a 4-week cycle. Patients were stratified by prior systemic treatment, M1 subclass, and baseline lactate dehydrogenase (LDH) levels. The primary end point was PFS. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> The study did not achieve its PFS end point (hazard ratio, 0.89; P = .23). The study was stopped when an early overall survival data analysis indicated an imbalance in total deaths favoring paclitaxel, predominantly in patients with high LDH levels. A prospectively defined subgroup analysis revealed a statistically significant improvement in median PFS for the combination in patients with normal baseline LDH. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> The addition of elesclomol to paclitaxel did not significantly improve PFS in unselected patients with advanced melanoma. The association between baseline LDH and clinical outcomes suggests that LDH may be a predictive factor for treatment with this combination, consistent with recent findings on the association between elesclomol anticancer activity and cellular metabolic state. </jats:p></jats:sec>", "DOI": "10.1200/jco.2012.44.5585", "type": "journal-article", "created": {"date-parts": [[2013, 2, 12]], "date-time": "2013-02-12T04:03:57Z", "timestamp": 1360641837000}, "page": "1211-1218", "source": "Crossref", "is-referenced-by-count": 41, "title": ["Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma"], "prefix": "10.1200", "volume": "31", "author": [{"given": "Steven J.", "family": "O'Day", "sequence": "first", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Alexander M.M.", "family": "Eggermont", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Vanna", "family": "Chiarion-Sileni", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Richard", "family": "Kefford", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Jean Jacques", "family": "Grob", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Laurent", "family": "Mortier", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Caroline", "family": "Robert", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Jacob", "family": "Schachter", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Alessandro", "family": "Testori", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Jacek", "family": "Mackiewicz", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Philip", "family": "Friedlander", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Claus", "family": "Garbe", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Selma", "family": "Ugurel", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Frances", "family": "Collichio", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Wei", "family": "Guo", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Joelle", "family": "Lufkin", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Safi", "family": "Bahcall", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Vojo", "family": "Vukovic", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}, {"given": "Axel", "family": "Hauschild", "sequence": "additional", "affiliation": [{"name": "Steven J. O'Day, The Beverly Hills Cancer Center, Beverly Hills, CA; Alexander M.M. Eggermont, Institut de Canc\u00e9rologie Gustave Roussy, Paris; Jean Jacques Grob, Hopital de la Timone, Marseille; Laurent Mortier, Centre Hospitalier R\u00e9gional et Universitaire, Lille; Caroline Robert, Institut Gustave Roussy, Villejuif, France; Vanna Chiarion-Sileni, Istituto Oncologico Veneto-Istituti di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Richard..."}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.44.5585", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T20:37:00Z", "timestamp": 1574887020000}, "score": 77.14337, "issued": {"date-parts": [[2013, 3, 20]]}, "references-count": 32, "journal-issue": {"published-print": {"date-parts": [[2013, 3, 20]]}, "issue": "9"}, "alternative-id": ["10.1200/JCO.2012.44.5585"], "URL": "http://dx.doi.org/10.1200/jco.2012.44.5585", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:59:16Z", "timestamp": 1576799956623}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "18_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2009, 6, 20]]}, "abstract": "<jats:p> LBA9012 </jats:p><jats:p> Background: Elesclomol is an investigational first-in-class oxidative stress inducer that increases oxidative stress in cancer cells leading to mitochondria-induced apoptosis. Methods: Patients (pts) with Stage IV MM, no prior chemotherapy, LDH \u03bc 2\u00d7 ULN were randomized (1:1) to either 213 mg/m<jats:sup>2</jats:sup> elesclomol in combination with 80 mg/m<jats:sup>2</jats:sup> paclitaxel (ELPAC) or 80 mg/m<jats:sup>2</jats:sup> paclitaxel alone (P); both were given weekly \u00d73 followed by 1 week rest until disease progression. Pts were stratified by prior non-cytotoxic treatment, M1 grade, and LDH. The primary endpoint was PFS with &gt;90% power to detect a 2-month improvement. The primary PFS analysis was planned once all pts had been enrolled and at least 164 PFS events had occurred. Results: 651 pts were enrolled between September 2007 and February 2009. Prognostic factors were generally well balanced. PFS analysis was based on investigator assessment of 411 pts (219 events). Median PFS was 3.5 m (95% CI 2.7\u20133.7) in ELPAC and 1.9 m (95% CI 1.9\u20133.3) in P [HR 0.88; 95% CI 0.67\u20131.16, p=0.3695]. The median number of cycles was 3 in ELPAC and 2 in P. Safety analysis showed increased signals on ELPAC including increased \u2265Gr 3 AEs (N=405, 32.8% vs. 23.5%), increased AEs leading to death (N=405, 3.5% vs &lt;1%) and increased overall deaths (N=651, 80 vs 53; 80% censored). Most common AEs in ELPAC were fatigue (32.8%), alopecia (31.3%) and nausea (27.9%). Conclusions: There was an improvement in PFS in the ELPAC arm, but it did not achieve statistical significance. In February 2009, the study was halted based on the recommendation of the DMC to unblind the study after the DMC observed increased deaths on the ELPAC arm. The DMC could not determine whether the observed increased deaths were treatment related or not. Of note, in this analysis there were no specific target organ toxicities attributable to ELPAC that could explain the imbalance of deaths. OS data continues to be collected to determine if the observed imbalance in OS persists as the data mature. </jats:p><jats:p> [Table: see text] </jats:p>", "DOI": "10.1200/jco.2009.27.18_suppl.lba9012", "type": "journal-article", "created": {"date-parts": [[2017, 2, 23]], "date-time": "2017-02-23T18:51:22Z", "timestamp": 1487875882000}, "page": "LBA9012-LBA9012", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM)"], "prefix": "10.1200", "volume": "27", "author": [{"given": "A.", "family": "Hauschild", "sequence": "first", "affiliation": [{"name": "University of Kiel, Kiel, Germany; Erasmus University Medical Center, Rotterdam, Netherlands; Synta Pharmaceuticals Corporation, Lexington, MA; The Angeles Clinic and Research Institute, Santa Monica, CA"}]}, {"given": "A. M.", "family": "Eggermont", "sequence": "additional", "affiliation": [{"name": "University of Kiel, Kiel, Germany; Erasmus University Medical Center, Rotterdam, Netherlands; Synta Pharmaceuticals Corporation, Lexington, MA; The Angeles Clinic and Research Institute, Santa Monica, CA"}]}, {"given": "E.", "family": "Jacobson", "sequence": "additional", "affiliation": [{"name": "University of Kiel, Kiel, Germany; Erasmus University Medical Center, Rotterdam, Netherlands; Synta Pharmaceuticals Corporation, Lexington, MA; The Angeles Clinic and Research Institute, Santa Monica, CA"}]}, {"given": "S. J.", "family": "O'Day", "sequence": "additional", "affiliation": [{"name": "University of Kiel, Kiel, Germany; Erasmus University Medical Center, Rotterdam, Netherlands; Synta Pharmaceuticals Corporation, Lexington, MA; The Angeles Clinic and Research Institute, Santa Monica, CA"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2009.27.18_suppl.lba9012", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:44:31Z", "timestamp": 1574891071000}, "score": 70.62366, "issued": {"date-parts": [[2009, 6, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 6, 20]]}, "issue": "18_suppl"}, "alternative-id": ["10.1200/jco.2009.27.18_suppl.lba9012"], "URL": "http://dx.doi.org/10.1200/jco.2009.27.18_suppl.lba9012", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:59:16Z", "timestamp": 1576799956892}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "18S", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2009, 6, 20]]}, "DOI": "10.1200/jco.2009.27.18s.lba9012", "type": "journal-article", "created": {"date-parts": [[2017, 2, 23]], "date-time": "2017-02-23T17:37:44Z", "timestamp": 1487871464000}, "page": "LBA9012-LBA9012", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM)"], "prefix": "10.1200", "volume": "27", "author": [{"given": "A.", "family": "Hauschild", "sequence": "first", "affiliation": [{"name": "University of Kiel, Kiel, Germany; Erasmus University Medical Center, Rotterdam, Netherlands; Synta Pharmaceuticals Corporation, Lexington, MA; The Angeles Clinic and Research Institute, Santa Monica, CA"}]}, {"given": "A. M.", "family": "Eggermont", "sequence": "additional", "affiliation": [{"name": "University of Kiel, Kiel, Germany; Erasmus University Medical Center, Rotterdam, Netherlands; Synta Pharmaceuticals Corporation, Lexington, MA; The Angeles Clinic and Research Institute, Santa Monica, CA"}]}, {"given": "E.", "family": "Jacobson", "sequence": "additional", "affiliation": [{"name": "University of Kiel, Kiel, Germany; Erasmus University Medical Center, Rotterdam, Netherlands; Synta Pharmaceuticals Corporation, Lexington, MA; The Angeles Clinic and Research Institute, Santa Monica, CA"}]}, {"given": "S. J.", "family": "O'Day", "sequence": "additional", "affiliation": [{"name": "University of Kiel, Kiel, Germany; Erasmus University Medical Center, Rotterdam, Netherlands; Synta Pharmaceuticals Corporation, Lexington, MA; The Angeles Clinic and Research Institute, Santa Monica, CA"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2009.27.18s.lba9012", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T22:21:23Z", "timestamp": 1574893283000}, "score": 70.62366, "issued": {"date-parts": [[2009, 6, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 6, 20]]}, "issue": "18S"}, "alternative-id": ["10.1200/jco.2009.27.18s.lba9012"], "URL": "http://dx.doi.org/10.1200/jco.2009.27.18s.lba9012", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:59:57Z", "timestamp": 1576799997890}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "15_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2010, 5, 20]]}, "DOI": "10.1200/jco.2010.28.15_suppl.8550", "type": "journal-article", "created": {"date-parts": [[2017, 2, 24]], "date-time": "2017-02-24T02:41:10Z", "timestamp": 1487904070000}, "page": "8550-8550", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update."], "prefix": "10.1200", "volume": "28", "author": [{"given": "V. M.", "family": "Vukovic", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Hauschild", "sequence": "additional", "affiliation": []}, {"given": "A. M.", "family": "Eggermont", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "O'Day", "sequence": "additional", "affiliation": []}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2010.28.15_suppl.8550", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T22:04:54Z", "timestamp": 1574892294000}, "score": 68.64356, "issued": {"date-parts": [[2010, 5, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 5, 20]]}, "issue": "15_suppl"}, "alternative-id": ["10.1200/jco.2010.28.15_suppl.8550"], "URL": "http://dx.doi.org/10.1200/jco.2010.28.15_suppl.8550", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T20:12:43Z", "timestamp": 1574107963637}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2001, 4, 1]], "date-time": "2001-04-01T00:00:00Z", "timestamp": 986083200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2001, 4]]}, "DOI": "10.1016/s0959-8049(01)80586-4", "type": "journal-article", "created": {"date-parts": [[2003, 12, 10]], "date-time": "2003-12-10T12:24:32Z", "timestamp": 1071059072000}, "page": "S28-S29", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced NSCLC. Final results of a randomized phase III study"], "prefix": "10.1016", "volume": "37", "author": [{"given": "P.", "family": "Kosmidis", "sequence": "first", "affiliation": []}, {"given": "C.", "family": "Bacoyiannis", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Mylonakis", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Nicolaides", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Kalophonos", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Samantas", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Boukovinas", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Skarlos", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Papakostas", "sequence": "additional", "affiliation": []}, {"given": "M.A.", "family": "Dimoupoulos", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804901805864?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804901805864?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 16]], "date-time": "2019-02-16T09:55:52Z", "timestamp": 1550310952000}, "score": 57.493336, "issued": {"date-parts": [[2001, 4]]}, "references-count": 0, "alternative-id": ["S0959804901805864"], "URL": "http://dx.doi.org/10.1016/s0959-8049(01)80586-4", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T04:16:10Z", "timestamp": 1575173770327}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2005, 7, 1]], "date-time": "2005-07-01T00:00:00Z", "timestamp": 1120176000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2005, 7]]}, "DOI": "10.1016/s0169-5002(05)80215-6", "type": "journal-article", "created": {"date-parts": [[2005, 9, 7]], "date-time": "2005-09-07T19:17:09Z", "timestamp": 1126120629000}, "page": "S30", "source": "Crossref", "is-referenced-by-count": 11, "title": ["O-082 A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)"], "prefix": "10.1016", "volume": "49", "author": [{"given": "G.", "family": "Blumenschein", "sequence": "first", "affiliation": []}, {"given": "C.", "family": "Ludwig", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Thomas", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Tan", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Fanucchi", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Santoro", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Crawford", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Breton", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "O'Brien", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Khuri", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500205802156?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500205802156?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 22]], "date-time": "2019-01-22T14:25:18Z", "timestamp": 1548167118000}, "score": 56.752964, "issued": {"date-parts": [[2005, 7]]}, "references-count": 0, "alternative-id": ["S0169500205802156"], "URL": "http://dx.doi.org/10.1016/s0169-5002(05)80215-6", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Pulmonary and Respiratory Medicine"]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:59:35Z", "timestamp": 1575305975174}, "reference-count": 28, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2006, 5, 1]], "date-time": "2006-05-01T00:00:00Z", "timestamp": 1146441600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Lung Cancer"], "published-print": {"date-parts": [[2006, 5]]}, "DOI": "10.3816/clc.2006.n.027", "type": "journal-article", "created": {"date-parts": [[2008, 9, 11]], "date-time": "2008-09-11T01:08:42Z", "timestamp": 1221095322000}, "page": "417-419", "source": "Crossref", "is-referenced-by-count": 39, "title": ["PIONEER: A Phase III Randomized Trial of Paclitaxel Poliglumex Versus Paclitaxel in Chemotherapy-Naive Women with Advanced-Stage Non-Small-Cell Lung Cancer and Performance Status of 2"], "prefix": "10.3816", "volume": "7", "author": [{"given": "Kathy S.", "family": "Albain", "sequence": "first", "affiliation": []}, {"given": "Chandra P.", "family": "Belani", "sequence": "additional", "affiliation": []}, {"given": "Philip", "family": "Bonomi", "sequence": "additional", "affiliation": []}, {"given": "Kenneth J.", "family": "O'Byrne", "sequence": "additional", "affiliation": []}, {"given": "Joan H.", "family": "Schiller", "sequence": "additional", "affiliation": []}, {"given": "Mark", "family": "Socinski", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1525730411707136?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1525730411707136?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 13]], "date-time": "2019-05-13T23:01:58Z", "timestamp": 1557788518000}, "score": 55.123375, "issued": {"date-parts": [[2006, 5]]}, "references-count": 28, "journal-issue": {"published-print": {"date-parts": [[2006, 5]]}, "issue": "6"}, "alternative-id": ["S1525730411707136"], "URL": "http://dx.doi.org/10.3816/clc.2006.n.027", "ISSN": ["1525-7304"], "issn-type": [{"value": "1525-7304", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Pulmonary and Respiratory Medicine"]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:59:57Z", "timestamp": 1576799997662}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "15_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2010, 5, 20]]}, "DOI": "10.1200/jco.2010.28.15_suppl.8511", "type": "journal-article", "created": {"date-parts": [[2017, 2, 24]], "date-time": "2017-02-24T02:41:10Z", "timestamp": 1487904070000}, "page": "8511-8511", "source": "Crossref", "is-referenced-by-count": 33, "title": ["Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma."], "prefix": "10.1200", "volume": "28", "author": [{"given": "K. T.", "family": "Flaherty", "sequence": "first", "affiliation": []}, {"given": "S. J.", "family": "Lee", "sequence": "additional", "affiliation": []}, {"given": "L. M.", "family": "Schuchter", "sequence": "additional", "affiliation": []}, {"given": "L. E.", "family": "Flaherty", "sequence": "additional", "affiliation": []}, {"given": "J. J.", "family": "Wright", "sequence": "additional", "affiliation": []}, {"given": "P. D.", "family": "Leming", "sequence": "additional", "affiliation": []}, {"given": "J. M.", "family": "Kirkwood", "sequence": "additional", "affiliation": []}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2010.28.15_suppl.8511", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T22:04:52Z", "timestamp": 1574892292000}, "score": 54.66246, "issued": {"date-parts": [[2010, 5, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 5, 20]]}, "issue": "15_suppl"}, "alternative-id": ["10.1200/jco.2010.28.15_suppl.8511"], "URL": "http://dx.doi.org/10.1200/jco.2010.28.15_suppl.8511", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:58:01Z", "timestamp": 1576799881372}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "16_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2005, 6]]}, "DOI": "10.1200/jco.2005.23.16_suppl.lba7011", "type": "journal-article", "created": {"date-parts": [[2017, 2, 23]], "date-time": "2017-02-23T18:55:09Z", "timestamp": 1487876109000}, "page": "LBA7011-LBA7011", "source": "Crossref", "is-referenced-by-count": 13, "title": ["Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-na\u00efve advanced non-small cell lung cancer (NSCLC): A phase III study"], "prefix": "10.1200", "volume": "23", "author": [{"given": "C. J.", "family": "Langer", "sequence": "first", "affiliation": [{"name": "Fox Chase Cancer Ctr, Philadelphia, PA; Univ of North Carolina at Chapel Hill, Chapel Hill, NC; St. James\u2019s Hosp, Dublin, Ireland"}]}, {"given": "M. A.", "family": "Socinski", "sequence": "additional", "affiliation": [{"name": "Fox Chase Cancer Ctr, Philadelphia, PA; Univ of North Carolina at Chapel Hill, Chapel Hill, NC; St. James\u2019s Hosp, Dublin, Ireland"}]}, {"given": "K. J.", "family": "O\u2019Byrne", "sequence": "additional", "affiliation": [{"name": "Fox Chase Cancer Ctr, Philadelphia, PA; Univ of North Carolina at Chapel Hill, Chapel Hill, NC; St. James\u2019s Hosp, Dublin, Ireland"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.lba7011", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:01:37Z", "timestamp": 1574888497000}, "score": 50.490227, "issued": {"date-parts": [[2005, 6]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2005, 6]]}, "issue": "16_suppl"}, "alternative-id": ["10.1200/jco.2005.23.16_suppl.lba7011"], "URL": "http://dx.doi.org/10.1200/jco.2005.23.16_suppl.lba7011", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:58:52Z", "timestamp": 1576799932968}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "15_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2008, 5, 20]]}, "DOI": "10.1200/jco.2008.26.15_suppl.5030", "type": "journal-article", "created": {"date-parts": [[2017, 2, 24]], "date-time": "2017-02-24T07:33:44Z", "timestamp": 1487921624000}, "page": "5030-5030", "source": "Crossref", "is-referenced-by-count": 13, "title": ["Randomized phase III trial of 2nd line gemcitabine/paclitaxel chemotherapy in patients with advanced bladder cancer: Temporary versus maintenance treatment (German Association of Urologic Oncology (AUO) Trial AB 20/99)"], "prefix": "10.1200", "volume": "26", "author": [{"given": "P.", "family": "Albers", "sequence": "first", "affiliation": []}, {"given": "R.", "family": "Siener", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Park", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Fechner", "sequence": "additional", "affiliation": []}, {"given": "U.", "family": "Steiner", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Lehmann", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Heimbach", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Heidenreich", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Fimmers", "sequence": "additional", "affiliation": []}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2008.26.15_suppl.5030", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T22:11:23Z", "timestamp": 1574892683000}, "score": 50.43415, "issued": {"date-parts": [[2008, 5, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2008, 5, 20]]}, "issue": "15_suppl"}, "alternative-id": ["10.1200/jco.2008.26.15_suppl.5030"], "URL": "http://dx.doi.org/10.1200/jco.2008.26.15_suppl.5030", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:58:01Z", "timestamp": 1576799881313}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "16_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2005, 6]]}, "DOI": "10.1200/jco.2005.23.16_suppl.lba7001", "type": "journal-article", "created": {"date-parts": [[2017, 2, 23]], "date-time": "2017-02-23T18:55:09Z", "timestamp": 1487876109000}, "page": "LBA7001-LBA7001", "source": "Crossref", "is-referenced-by-count": 11, "title": ["A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)"], "prefix": "10.1200", "volume": "23", "author": [{"given": "G. R.", "family": "Blumenschein", "sequence": "first", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}, {"given": "F.", "family": "Khuri", "sequence": "additional", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}, {"given": "U.", "family": "Gatzemeier", "sequence": "additional", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}, {"given": "W. H.", "family": "Miller", "sequence": "additional", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}, {"given": "J.", "family": "von Pawel", "sequence": "additional", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}, {"given": "J. R.", "family": "Rigas", "sequence": "additional", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}, {"given": "R. S.", "family": "Herbst", "sequence": "additional", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}, {"given": "Z.", "family": "Dziewanowska", "sequence": "additional", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}, {"given": "A.", "family": "Negro-Vilar", "sequence": "additional", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}, {"given": "M.", "family": "Mabry", "sequence": "additional", "affiliation": [{"name": "UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.lba7001", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:50:43Z", "timestamp": 1574891443000}, "score": 49.996395, "issued": {"date-parts": [[2005, 6]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2005, 6]]}, "issue": "16_suppl"}, "alternative-id": ["10.1200/jco.2005.23.16_suppl.lba7001"], "URL": "http://dx.doi.org/10.1200/jco.2005.23.16_suppl.lba7001", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T04:11:50Z", "timestamp": 1574568710729}, "reference-count": 12, "publisher": "Oxford University Press (OUP)", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Japanese Journal of Clinical Oncology"], "published-print": {"date-parts": [[2015, 3, 1]]}, "DOI": "10.1093/jjco/hyu205", "type": "journal-article", "created": {"date-parts": [[2014, 12, 17]], "date-time": "2014-12-17T05:59:23Z", "timestamp": 1418795963000}, "page": "303-306", "source": "Crossref", "is-referenced-by-count": 11, "title": ["A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)"], "prefix": "10.1093", "volume": "45", "author": [{"given": "W.", "family": "Koizumi", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Morita", "sequence": "additional", "affiliation": []}, {"given": "Y.", "family": "Sakata", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2014, 12, 16]]}, "reference": [{"issue": "1", "key": "3_21842394", "doi-asserted-by": "publisher", "first-page": "14", "DOI": "10.1007/s10120-005-0351-6", "volume": "9", "author": "Hironaka", "year": "2006", "journal-title": "Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association", "ISSN": "http://id.crossref.org/issn/1436-3291", "issn-type": "print"}, {"key": "4_38122728", "ISSN": "http://id.crossref.org/issn/0732-183X", "issn-type": "print", "volume": "28", "first-page": "S15", "year": "2010", "journal-title": "Journal of Clinical Oncology"}, {"issue": "3", "key": "5_30554596", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1016/S1470-2045(08)70035-4", "volume": "9", "author": "Koizumi", "year": "2008", "journal-title": "The lancet oncology", "ISSN": "http://id.crossref.org/issn/1470-2045", "issn-type": "print"}, {"issue": "11", "key": "6_35741921", "doi-asserted-by": "publisher", "first-page": "1063", "DOI": "10.1016/S1470-2045(09)70259-1", "volume": "10", "author": "Boku", "year": "2009", "journal-title": "The lancet oncology", "ISSN": "http://id.crossref.org/issn/1470-2045", "issn-type": "print"}, {"issue": "15", "key": "7_40322122", "doi-asserted-by": "publisher", "first-page": "2306", "DOI": "10.1016/j.ejca.2011.06.002", "volume": "47", "author": "Thuss-Patience", "year": "2011", "journal-title": "European journal of cancer (Oxford, England : 1990)", "ISSN": "http://id.crossref.org/issn/0959-8049", "issn-type": "print"}, {"issue": "13", "key": "8_42121349", "doi-asserted-by": "publisher", "first-page": "1513", "DOI": "10.1200/JCO.2011.39.4585", "volume": "30", "year": "2012", "journal-title": "Journal of Clinical Oncology", "ISSN": "http://id.crossref.org/issn/0732-183X", "issn-type": "print"}, {"key": "9_47283652", "ISSN": "http://id.crossref.org/issn/1470-2045", "issn-type": "print", "volume": "15", "first-page": "78", "year": "2014", "journal-title": "The lancet oncology", "DOI": "10.1016/S1470-2045(13)70549-7", "doi-asserted-by": "crossref"}, {"key": "10_49408480", "ISSN": "http://id.crossref.org/issn/0732-183X", "issn-type": "print", "volume": "31", "first-page": "4438", "year": "2014", "journal-title": "Journal of Clinical Oncology"}, {"issue": "3", "key": "11_9704737", "doi-asserted-by": "crossref", "first-page": "344", "DOI": "10.1007/BF00197271", "volume": "88", "author": "Goedde", "year": "1992", "journal-title": "Human genetics", "ISSN": "http://id.crossref.org/issn/0340-6717", "issn-type": "print"}, {"issue": "5", "key": "12_17048264", "first-page": "1038", "volume": "8", "author": "Ibrahim", "year": "2002", "journal-title": "Clinical Cancer Research", "ISSN": "http://id.crossref.org/issn/1078-0432", "issn-type": "print"}, {"issue": "31", "key": "13_19507915", "doi-asserted-by": "publisher", "first-page": "7785", "DOI": "10.1200/JCO.2004.00.6148", "volume": "23", "author": "Nyman", "year": "2005", "journal-title": "Journal of Clinical Oncology", "ISSN": "http://id.crossref.org/issn/0732-183X", "issn-type": "print"}, {"key": "14_49408481", "ISSN": "http://id.crossref.org/issn/0910-5050", "issn-type": "print", "volume": "105", "first-page": "812", "year": "2014", "journal-title": "Cancer Science", "DOI": "10.1111/cas.12419", "doi-asserted-by": "crossref"}], "container-title": ["Japanese Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/jjco/article-pdf/45/3/303/6959041/hyu205.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 24]], "date-time": "2017-08-24T12:57:31Z", "timestamp": 1503579451000}, "score": 48.883255, "issued": {"date-parts": [[2014, 12, 16]]}, "references-count": 12, "journal-issue": {"published-online": {"date-parts": [[2015, 2, 25]]}, "published-print": {"date-parts": [[2015, 3, 1]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1093/jjco/hyu205", "relation": {"cites": []}, "ISSN": ["0368-2811", "1465-3621"], "issn-type": [{"value": "0368-2811", "type": "print"}, {"value": "1465-3621", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:59:02Z", "timestamp": 1574539142478}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 11]]}, "DOI": "10.1158/1535-7163.targ-13-a77", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T22:27:17Z", "timestamp": 1408055237000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Abstract A77: Randomized phase II study comparing paclitaxel/carboplatin intercalated with gefitinib to paclitaxel/carboplatin alone for chemotherapy-naive non-small cell lung cancer patients either with history of smoking or with wild-type EGFR."], "prefix": "10.1158", "author": [{"given": "Dae Ho", "family": "Lee", "sequence": "first", "affiliation": []}, {"given": "Jeong Eun", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "Yoon J.", "family": "Choi", "sequence": "additional", "affiliation": []}, {"given": "Chang Min", "family": "Choi", "sequence": "additional", "affiliation": []}, {"given": "Jung-Shin", "family": "Lee", "sequence": "additional", "affiliation": []}, {"given": "Sang-We", "family": "Kim", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 1, 30]]}, "event": {"name": "Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA"}, "container-title": ["Clinical Trials"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1535-7163.TARG-13-A77", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T19:39:13Z", "timestamp": 1557430753000}, "score": 48.8618, "issued": {"date-parts": [[2013, 11]]}, "references-count": 0, "alternative-id": ["10.1158/1535-7163.TARG-13-A77"], "URL": "http://dx.doi.org/10.1158/1535-7163.targ-13-a77"}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:59:32Z", "timestamp": 1576799972667}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "15_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2010, 5, 20]]}, "DOI": "10.1200/jco.2010.28.15_suppl.4015", "type": "journal-article", "created": {"date-parts": [[2017, 2, 24]], "date-time": "2017-02-24T02:41:10Z", "timestamp": 1487904070000}, "page": "4015-4015", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report."], "prefix": "10.1200", "volume": "28", "author": [{"given": "T.", "family": "Kishimoto", "sequence": "first", "affiliation": []}, {"given": "H.", "family": "Imamura", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Uedou", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Fujitani", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Iijima", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Takiuchi", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Imano", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Shimokawa", "sequence": "additional", "affiliation": []}, {"given": "Y.", "family": "Kurokawa", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Furukawa", "sequence": "additional", "affiliation": []}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2010.28.15_suppl.4015", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T22:16:55Z", "timestamp": 1574893015000}, "score": 48.851707, "issued": {"date-parts": [[2010, 5, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 5, 20]]}, "issue": "15_suppl"}, "alternative-id": ["10.1200/jco.2010.28.15_suppl.4015"], "URL": "http://dx.doi.org/10.1200/jco.2010.28.15_suppl.4015", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T17:20:22Z", "timestamp": 1574356822247}, "reference-count": 29, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2008, 5, 1]], "date-time": "2008-05-01T00:00:00Z", "timestamp": 1209600000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Gynecologic Oncology"], "published-print": {"date-parts": [[2008, 5]]}, "DOI": "10.1016/j.ygyno.2008.01.005", "type": "journal-article", "created": {"date-parts": [[2008, 3, 11]], "date-time": "2008-03-11T14:51:46Z", "timestamp": 1205247106000}, "page": "174-181", "source": "Crossref", "is-referenced-by-count": 55, "title": ["Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival"], "prefix": "10.1016", "volume": "109", "author": [{"given": "David S.", "family": "Alberts", "sequence": "first", "affiliation": []}, {"given": "Christian", "family": "Marth", "sequence": "additional", "affiliation": []}, {"given": "Ronald D.", "family": "Alvarez", "sequence": "additional", "affiliation": []}, {"given": "Gary", "family": "Johnson", "sequence": "additional", "affiliation": []}, {"given": "Mariusz", "family": "Bidzinski", "sequence": "additional", "affiliation": []}, {"given": "David R.", "family": "Kardatzke", "sequence": "additional", "affiliation": []}, {"given": "Williamson Z.", "family": "Bradford", "sequence": "additional", "affiliation": []}, {"given": "Jeff", "family": "Loutit", "sequence": "additional", "affiliation": []}, {"given": "David H.", "family": "Kirn", "sequence": "additional", "affiliation": []}, {"given": "Mary C.", "family": "Clouser", "sequence": "additional", "affiliation": []}, {"given": "Maurie", "family": "Markman", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Gynecologic Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0090825808000085?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0090825808000085?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T00:00:17Z", "timestamp": 1557360017000}, "score": 48.68029, "issued": {"date-parts": [[2008, 5]]}, "references-count": 29, "journal-issue": {"published-print": {"date-parts": [[2008, 5]]}, "issue": "2"}, "alternative-id": ["S0090825808000085"], "URL": "http://dx.doi.org/10.1016/j.ygyno.2008.01.005", "ISSN": ["0090-8258"], "issn-type": [{"value": "0090-8258", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 21]], "date-time": "2019-12-21T11:23:18Z", "timestamp": 1576927398328}, "reference-count": 28, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2011, 4, 1]], "date-time": "2011-04-01T00:00:00Z", "timestamp": 1301616000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Breast Cancer"], "published-print": {"date-parts": [[2011, 4]]}, "DOI": "10.1016/j.clbc.2011.03.005", "type": "journal-article", "created": {"date-parts": [[2011, 5, 20]], "date-time": "2011-05-20T23:02:09Z", "timestamp": 1305932529000}, "page": "82-92", "source": "Crossref", "is-referenced-by-count": 81, "title": ["Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial"], "prefix": "10.1016", "volume": "11", "author": [{"given": "Nicholas J.", "family": "Robert", "sequence": "first", "affiliation": []}, {"given": "Mansoor N.", "family": "Saleh", "sequence": "additional", "affiliation": []}, {"given": "Devchand", "family": "Paul", "sequence": "additional", "affiliation": []}, {"given": "Daniele", "family": "Generali", "sequence": "additional", "affiliation": []}, {"given": "Laurent", "family": "Gressot", "sequence": "additional", "affiliation": []}, {"given": "Mehmet S.", "family": "Copur", "sequence": "additional", "affiliation": []}, {"given": "Adam M.", "family": "Brufsky", "sequence": "additional", "affiliation": []}, {"given": "Susan E.", "family": "Minton", "sequence": "additional", "affiliation": []}, {"given": "Jeffrey K.", "family": "Giguere", "sequence": "additional", "affiliation": []}, {"suffix": "II", "given": "John W.", "family": "Smith", "sequence": "additional", "affiliation": []}, {"given": "Paul D.", "family": "Richards", "sequence": "additional", "affiliation": []}, {"given": "Diana", "family": "Gernhardt", "sequence": "additional", "affiliation": []}, {"given": "Xin", "family": "Huang", "sequence": "additional", "affiliation": []}, {"given": "Katherine F.", "family": "Liau", "sequence": "additional", "affiliation": []}, {"given": "Kenneth A.", "family": "Kern", "sequence": "additional", "affiliation": []}, {"given": "John", "family": "Davis", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Breast Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1526820911000061?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1526820911000061?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 2]], "date-time": "2018-12-02T19:22:53Z", "timestamp": 1543778573000}, "score": 48.593487, "issued": {"date-parts": [[2011, 4]]}, "references-count": 28, "journal-issue": {"published-print": {"date-parts": [[2011, 4]]}, "issue": "2"}, "alternative-id": ["S1526820911000061"], "URL": "http://dx.doi.org/10.1016/j.clbc.2011.03.005", "ISSN": ["1526-8209"], "issn-type": [{"value": "1526-8209", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T10:18:13Z", "timestamp": 1575454693411}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2019, 2, 15]]}, "DOI": "10.1158/1538-7445.sabcs18-p1-14-01", "type": "proceedings-article", "created": {"date-parts": [[2019, 5, 11]], "date-time": "2019-05-11T19:14:08Z", "timestamp": 1557602048000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract P1-14-01: Final results of NorBreast-231, a randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel as first-line chemotherapy in patients with advanced breast cancer"], "prefix": "10.1158", "author": [{"given": "MS", "family": "Aapro", "sequence": "first", "affiliation": []}, {"given": "R", "family": "Hegg", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Ruiz Borrego", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Staroslawska", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Morales", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Cinieri", "sequence": "additional", "affiliation": []}, {"given": "R", "family": "De Freitas Junior", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Garcia Estevez", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Szombara", "sequence": "additional", "affiliation": []}, {"given": "H", "family": "Hervieu", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Groc", "sequence": "additional", "affiliation": []}, {"given": "GR", "family": "Villanova", "sequence": "additional", "affiliation": []}], "member": "1086", "event": {"name": "Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas"}, "container-title": ["Poster Session Abstracts"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.SABCS18-P1-14-01", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T19:38:50Z", "timestamp": 1558208330000}, "score": 48.19157, "issued": {"date-parts": [[2019, 2, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.SABCS18-P1-14-01"], "URL": "http://dx.doi.org/10.1158/1538-7445.sabcs18-p1-14-01"}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T14:20:54Z", "timestamp": 1574691654837}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl 3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Annals of Oncology"], "published-print": {"date-parts": [[2015, 5, 1]]}, "DOI": "10.1093/annonc/mdv113.01", "type": "journal-article", "created": {"date-parts": [[2015, 5, 7]], "date-time": "2015-05-07T11:35:31Z", "timestamp": 1430998531000}, "page": "iii1-iii1", "source": "Crossref", "is-referenced-by-count": 1, "title": ["1P * A phase III randomized study of paclitaxel and trastuzumab versus paclitaxel alone for early stage, ER and PR receptor negative and HER2-positive breast cancer as adjuvant treatment"], "prefix": "10.1093", "volume": "26", "author": [{"given": "M. K.", "family": "Singhal", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Kapoor", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Narayan", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Maharia", "sequence": "additional", "affiliation": []}, {"given": "R. K.", "family": "Nirban", "sequence": "additional", "affiliation": []}, {"given": "S. K.", "family": "Beniwal", "sequence": "additional", "affiliation": []}, {"given": "H. S.", "family": "Kumar", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2015, 5, 7]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/26/suppl_3/iii1/6675545/mdv113.01.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 22]], "date-time": "2017-08-22T13:47:46Z", "timestamp": 1503409666000}, "score": 48.1569, "issued": {"date-parts": [[2015, 5, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2015, 5, 7]]}, "published-print": {"date-parts": [[2015, 5, 1]]}, "issue": "suppl 3"}, "URL": "http://dx.doi.org/10.1093/annonc/mdv113.01", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T05:15:48Z", "timestamp": 1574745348960}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl_9", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016, 12]]}, "DOI": "10.1093/annonc/mdw577.019", "type": "journal-article", "created": {"date-parts": [[2017, 2, 3]], "date-time": "2017-02-03T17:12:42Z", "timestamp": 1486141962000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC"], "prefix": "10.1093", "volume": "27", "author": [{"given": "L.", "family": "Emens", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Adams", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Loi", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Schneeweiss", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Rugo", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Winer", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Barrios", "sequence": "additional", "affiliation": []}, {"given": "V.", "family": "Dieras", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "de la Haba-Rodriguez", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Gianni", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Kusuma", "sequence": "additional", "affiliation": []}, {"given": "S.Y.", "family": "Chui", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Schmid", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2016, 12, 20]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/27/suppl_9/mdw577.019/10241692/mdw577.019.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 24]], "date-time": "2017-08-24T18:10:31Z", "timestamp": 1503598231000}, "score": 47.903816, "issued": {"date-parts": [[2016, 12]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2016, 12, 20]]}, "published-print": {"date-parts": [[2016, 12]]}, "issue": "suppl_9"}, "URL": "http://dx.doi.org/10.1093/annonc/mdw577.019", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T15:00:27Z", "timestamp": 1574521227600}, "reference-count": 33, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 7, 1]], "date-time": "2013-07-01T00:00:00Z", "timestamp": 1372636800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["gynecologiconcology-online.net", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Gynecologic Oncology"], "published-print": {"date-parts": [[2013, 7]]}, "DOI": "10.1016/j.ygyno.2012.12.004", "type": "journal-article", "created": {"date-parts": [[2012, 12, 9]], "date-time": "2012-12-09T20:00:34Z", "timestamp": 1355083234000}, "page": "31-37", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 9, "title": ["A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)"], "prefix": "10.1016", "volume": "130", "clinical-trial-number": [{"clinical-trial-number": "nct00554229", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct00929162", "registry": "10.18810/clinical-trials-gov"}], "author": [{"given": "F.", "family": "Cognetti", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Bagnato", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Colombo", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Savarese", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Scambia", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Sehouli", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Wimberger", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Sorio", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Harter", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Mari", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "McIntosh", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Nathan", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Pemberton", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Baumann", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Gynecologic Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0090825812009511?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0090825812009511?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 20]], "date-time": "2018-10-20T09:31:10Z", "timestamp": 1540027870000}, "score": 47.58413, "issued": {"date-parts": [[2013, 7]]}, "references-count": 33, "journal-issue": {"published-print": {"date-parts": [[2013, 7]]}, "issue": "1"}, "alternative-id": ["S0090825812009511"], "URL": "http://dx.doi.org/10.1016/j.ygyno.2012.12.004", "ISSN": ["0090-8258"], "issn-type": [{"value": "0090-8258", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)", "name": "articletitle", "label": "Article Title"}, {"value": "Gynecologic Oncology", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ygyno.2012.12.004", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2012 Published by Elsevier Inc.", "name": "copyright", "label": "Copyright"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}